Samchundang Pharmaceutical, which once saw its stock price exceed 1 million won and ranked first in KOSDAQ market capitalization, has experienced a decline of over 18% due to a global market downturn. This drop is attributed to concerns over U.S. monetary tightening and a flight from risk assets, particularly impacting the recently surging pharmaceutical and biotech sectors.
On June 8, the Korea Exchange reported that Samchundang's shares closed at 239,000 won, down 18.15% (53,000 won) from the previous trading day. The stock opened at 270,500 won and fell to as low as 238,500 won during the day.
The sharp decline in stock price is linked to fears of U.S. monetary tightening and a significant drop in semiconductor stocks, which has triggered a broader aversion to risk assets. The U.S. non-farm payrolls for May exceeded market expectations, dampening hopes for interest rate cuts by the Federal Reserve, while tech stocks like NVIDIA and Micron plummeted, leading to a sell-off in the domestic market.
Particularly, the pharmaceutical and biotech sectors, which had seen substantial gains recently, are now facing increased selling pressure as investors seek to realize profits. Samchundang, noted for its rapid rise this year as a prominent growth stock, has been significantly affected by the deteriorating investor sentiment.
In March, the company’s stock price surged past 1 million won, driven by expectations surrounding the development of an oral GLP-1 treatment for obesity and diabetes, propelling it to the top of the KOSDAQ market capitalization rankings. However, subsequent management decisions regarding a block deal and the ensuing uncertainty surrounding a licensing agreement with a U.S. partner have shaken market confidence, leading to a reversal in stock performance.
Currently, Samchundang's stock price has fallen over 70% from its peak in March. The recent plunge has significantly reduced its market capitalization, impacting its status as a leading growth stock on KOSDAQ.
Market analysts suggest that short-term volatility may continue to exert selling pressure on overvalued growth stocks. However, they also note that expectations for improved performance due to the oral GLP-1 business and an increased share of high-margin products remain valid for Samchundang Pharmaceutical.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.